Guidelines for the clinical application of prophylactic human papillomavirus (HPV) vaccines in China (2025 edition)
Authors:
- Mingzhu LiMLMingzhu Li
- Fanghui ZhaoFZFanghui Zhao
- Rutie YinRYRutie Yin
- Xinyu WangXWXinyu Wang
- Qing CongQCQing Cong
- Shuang LiSLShuang Li
- Sui LongSLSui Long
- Beihua KongBKBeihua Kong
- Ding MaDMDing Ma
- Lihui WeiLWLihui Wei
Open Access
- 18 September 2025
- journal article
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 5 (3) , e000285
Abstract
Prophylactic human papillomavirus (HPV) vaccination is a primary preventive measure aimed at preventing HPV-related lesions and cancers by preventing HPV infection. With the continuous update of global data on HPV vaccination, seven academic societies—including the Chinese Society for Colposcopy and Cervical Pathology of China Healthy Birth Science Association and Chinese Society of Gynecological oncology, Chinese Medical Association and others—have jointly developed the Guidelines for the Clinical Application of Prophylactic Human Papillomavirus (HPV) Vaccines in China (2025 Edition). This guideline was based on the previous Chinese Expert Consensus on the Clinical Application of Human Papillomavirus Vaccines1 as well as current evidence-based medical research, China’s national conditions and clinical realities. The recommended categories of this guideline are listed in table 1.Keywords
Funding Information
- National key research and development program (2021YFC2701202, 2021YFC2701203)
This publication has 110 references indexed in Scilit:
- Human Papillomavirus Vaccination and Trends in Cervical Cancer Incidence and Mortality in the USJAMA Pediatrics, 2021
- Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell TransplantJAMA Oncology, 2020
- Efficacy, immunogenicity and safety of the AS04‐HPV‐16/18 vaccine in Chinese women aged 18‐25 years: End‐of‐study results from a phase II/III, randomised, controlled trialCancer Medicine, 2019
- The distribution and prevalence of human papillomavirus in women in mainland ChinaCancer, 2019
- Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in WomenJAMA, 2016
- Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc analysis from a randomized controlled trialInternational Journal of Cancer, 2016
- Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: A pooled analysis of 17 population‐based studiesInternational Journal of Cancer, 2012
- Human papillomavirus types in 115,789 HPV‐positive women: A meta‐analysis from cervical infection to cancerInternational Journal of Cancer, 2012
- Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18International Journal of Cancer, 2011
- Heritability of cervical tumoursInternational Journal of Cancer, 2000